ArticleJournal of cachexia, sarcopenia and muscle2020
Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients.
Article in Journal of cachexia, sarcopenia and muscle, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Evaluation of Weight Gain and Overall Survival of Men Versus Women With Advanced Non-Small Cell Lung Cancer.Journal of cachexia, sarcopenia and muscle · 2025Trial
- Early Nutritional Intervention in Patients with Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: A Phase II Prospective Study.Nutrients · 2025Trial
- Trial
- Trial
- Cancer cachexia: a caregiver and advocate perspective.Current opinion in supportive and palliative care · 2026Review
- Demographic and regional disparities in cancer cachexia-related mortality in the USA from 1999 to 2020 - A retrospective cross-sectional study.Future healthcare journal · 2026Article
- Exploratory analysis of associations among weight loss, oral function, and dysgeusia in patients with lung cancer undergoing chemotherapy.BMC oral health · 2025Article
- Prevalence and Development of Cachexia Before and After Diagnosis of Non-small Cell Lung Cancer.American journal of clinical oncology · 2025Article
- What Cachexia-Related Outcomes Are Measured in Lung Cancer Chemotherapy Clinical Trials?Cancers · 2025Article
- Tumor metabolome remolded by low dose mitochondrial uncoupler elicites robust CD8Cell death discovery · 2025Article
- The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes.Cancer medicine · 2025Article
- Diversity in chemotherapy-induced cachexia.American journal of physiology. Cell physiology · 2025Review
- Exploring the Relationship Between Dietary Phytochemical Index and Chemotherapy-Related Symptoms: Insights From a Cross-Sectional Study.Food science & nutrition · 2024Article
- Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.Journal of cachexia, sarcopenia and muscle · 2024Article
- The relationship between weight gain during chemotherapy and outcomes in patients with advanced non-small cell lung cancer.Journal of cachexia, sarcopenia and muscle · 2024Article
- Development and applicability of modified weight loss grading system in cancer: a real-world cohort study.Journal of cachexia, sarcopenia and muscle · 2023Article
- Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle.BJC reports · 2023Review
- Cardiac wasting in head and neck cancer and in cardiac autopsies from different cancer types: A study in a chemo-naïve setting.Journal of cachexia, sarcopenia and muscle · 2023Article
- Why We Should Look at Dinner Plates: Diet Changes in Cancer Patients.Current oncology (Toronto, Ont.) · 2023Article
- Changes in Body Weight, Body Composition, Phase Angle, and Resting Metabolic Rate in Male Patients with Stage IV Non-Small-Cell Lung Cancer Undergoing Therapy.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEligibility criteria and endpoints for cancer cachexia trials-and whether weight loss should be included-remain controversial. Although most cachexia trials enrol patients after initial cancer diagnosis, few studies have addressed whether weight loss well after a cancer diagnosis is prognostic.
methodsWe pooled data from non-small cell lung cancer patients from prospectively conducted trials within the Alliance for Clinical Trials in Oncology (1998-2008), a nationally funded infrastructure. We examined (i) weight data availability and weight changes and (ii) survival.
resultsA total of 822 patients were examined. Of these, 659 (80%) were on treatment at the beginning of Cycle 2 of chemotherapy; weight was available for 656 (80%). By Cycles 3 and 4, weight was available for 448 (55%) and 384 (47%), respectively. From baseline to immediately prior to Cycle 2, 208 (32%) gained weight; 225 (34%) lost <2% of baseline weight; and 223 (34% of 656) lost 2% or more. Median survival from the beginning of Cycle 2 was 13.0, 10.9, and 6.9 months for patients with weight gain, weight loss of <2%, and weight loss of 2% or more, respectively. In multivariate analyses, adjusted for age, sex, performance score, type of treatment, and body mass index, weight loss of 2% or more was associated with poor overall survival compared with weight gain [hazard ratio (HR) = 1.66; 95% confidence interval (CI): 1.33-2.07; P < 0.001] and compared with weight loss of <2% (HR = 1.57; 95% CI: 1.27-1.95; P < 0.001). Although weight loss of <2% was not associated with poorer overall survival compared with weight gain, it was associated with poorer progression-free survival (HR = 1.24; 95% CI: 1.01-1.51; P = 0.036). Similar findings were observed in a separate 255-patient validation cohort.
conclusionsWeight should be integrated into cancer cachexia trials because of its ease of frequent measurement and sustained prognostic association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.